Xeris Biopharma Holdings, Inc. XERS Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s long-term debt?
- Xeris Biopharma Holdings, Inc. (XERS) reported long-term debt of $221.22M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s long-term debt changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s long-term debt increased by 1.6% year-over-year, from $217.81M to $221.22M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s long-term debt?
- Over 5 years (2020 to 2025), Xeris Biopharma Holdings, Inc.'s long-term debt has grown at a 20.4% compound annual growth rate (CAGR), from $87.02M to $220.34M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.